<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thalidomide is a putative anti-<z:mpath ids='MPATH_177'>angiogenesis</z:mpath> agent that has significant anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> activity in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">haematological malignancies</z:e> with increased bone marrow <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, including <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (MM) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>Increased levels of the <z:chebi fb="0" ids="52290">mitogen</z:chebi> for <z:mpath ids='MPATH_177'>angiogenesis</z:mpath>, vascular endothelial growth factor (VEGF), correlate with worse survival in <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>A phase II trial of thalidomide was conducted in patients with relapsed- or refractory-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> previously treated with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>-containing regimens </plain></SENT>
<SENT sid="3" pm="."><plain>A total of 16 patients with refractory- or relapsed-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> were treated with thalidomide 200-800 mg orally daily (median dose 400 mg daily) for a median of 27 d (range, 3-94 d) </plain></SENT>
<SENT sid="4" pm="."><plain>Overall, one patient (6%) achieved complete remission (CR) lasting for 36 months, and two patients had a transient reduction in marrow blasts from 8% and 7% to less than 5% in both cases </plain></SENT>
<SENT sid="5" pm="."><plain>There was no correlation between reduction in levels of <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> markers and response </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicities related to thalidomide were significant, and precluded dose escalation beyond 400 mg orally daily in most patients </plain></SENT>
<SENT sid="7" pm="."><plain>Although there appears to be some evidence of biological activity, single agent thalidomide is not an optimal choice of therapy for salvaging patients with relapsed- or refractory-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="8" pm="."><plain>Thalidomide analogues with more potent immunomodulatory activities and more favourable toxicity profiles may offer more promise as anti-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> therapy </plain></SENT>
</text></document>